Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Novo Nordisk is about to take on a task that’s so far foiled its peers. The Danish drugmaker is aiming to expand the global obesity market, both by launching its GLP-1 drug Saxenda in additional countries and by lobbying to get obesity recognized as a chronic disease.
Novo Nordisk is navigating a tough stretch, thanks to stepped-up competition and new state laws that threaten to worsen pricing pressure in the U.S. But the drugmaker believes it can still come out ahead, provided it can capitalize on some impending drug launches.
WiseGuyReports.com adds “Novo Nordisk Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database. Posted via Industry Today. Follow us on Twitter @IndustryToday
Novo Nordisk is one step closer to approval for semaglutide, the weekly diabetes drug it sees as a best-in-class follow-up to its blockbuster daily injection, Victoza. Next up? FDA label discussions, payer talks and prep for a market tussle with Eli Lilly's Trulicity.
It's not often that a drug company alerts the media to FDA review documents filed ahead of an agency advisory panel hearing. But Novo Nordisk did just that Monday as its key GLP-1 drug semaglutide, a follow-up to blockbuster Victoza, preps for its close-up before agency experts.